Dissociative anesthetic that is roughly 10 times stronger than 4-MeO-PCP. May also have opioid or dopaminergic activity.
3-Methoxyphencyclidine (3-MeO-PCP) is a dissociative anesthetic drug that has been sold online as a research chemical. The compound was first synthesized in 1979 to investigate the structure-activity relationship of phencyclidine derivatives. The activity of 3-MeO-PCP in man was not described until 1999 when a chemist using the pseudonym John Q. Beagle wrote that 3-MeO-PCP was qualitatively similar to PCP with comparable potency.
Oral Threshold: 1.5-3 mg Light: 3-5mg Common: 5-8mg Strong: 8-12mg Heavy: 12mg+
Oral Onset: 20-40 minutes.
Insufflated Onset: 5-15 minutes
Duration for oral and insufflated: 3-5 hours +/- 1 hour depending on dose.
After-effects: 2-48 hours.
Do not drive or operate heavy machinery. Take extra precaution if going out in public on 3-MeO-PCP. Do not drink alcohol or take any other drugs.
3-MeO-PCP binds to the NMDAN-methyl-D-aspartate receptor. NMDA antagonists are often dissociatives. receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP. 3-MeO-PCP has a Ki of 20 nM for the NMDAN-methyl-D-aspartate receptor. NMDA antagonists are often dissociatives. receptor, 216 nM for the serotoninA monoamine neurotransmitter, biochemically derived from tryptophan, that is primarily found in the gastrointestinal (GI) tract, platelets, and central nervous system (CNS) of humans and animals. It is a well-known contributor to feelings of well-being. transporter and 42 for the sigma1 receptor
May be Class B in UK as an analog of MXEMethoxetamine.
May be illegal in the US as part of the Analog Act.